Alkermes Reports Mixed 2025 Results, Eyes Pipeline Growth in 2026
Event summary
- Alkermes reported financial results for Q4 and full-year 2025, with detailed earnings available on its investor relations website.
- The company provided financial expectations for 2026 during a conference call and webcast on February 25, 2026.
- Alkermes' portfolio includes treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy.
- Pipeline includes late-stage candidates for narcolepsy and idiopathic hypersomnia, and early-stage orexin 2 receptor agonists for ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease.
The big picture
Alkermes' focus on developing innovative medicines in neuroscience positions it within a growing sector driven by increasing demand for treatments for mental health and neurological disorders. The company's pipeline, particularly in ADHD and fatigue associated with chronic diseases, aligns with broader industry trends towards addressing unmet needs in these areas. However, the competitive landscape and regulatory hurdles remain significant challenges.
What we're watching
- Pipeline Progress
- How the advancement of late-stage candidates for narcolepsy and idiopathic hypersomnia will impact Alkermes' growth prospects.
- Market Positioning
- Whether Alkermes can sustain its market position in the competitive neuroscience therapeutics space.
- Financial Performance
- The pace at which Alkermes can achieve its financial expectations for 2026, given the mixed results from 2025.
Related topics